JonesResearch analyst Soumit Roy initiated coverage of Cullinan Oncology with a Buy rating and $22 price target. The company has a potential best in class inhibitor of EGFR exon 20 mutations in non-small cell lung cancer, the analyst tells investors in a research note. The firm says Cullinan has a multiple shots on goal with a “robust” pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CGEM:
- Cullinan Oncology price target lowered to $34 from $39 at H.C. Wainwright
- Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Cullinan Oncology reports Q2 EPS (82c), consensus (97c)
- Cullinan Oncology announces first patient dosed in Phase 1 trial of CLN-978
- Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
